Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Todd Druley MD Appointed ANGLE plc CMO

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Todd Druley MD: ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces the appointment of Todd Druley, M.D., PhD. in the newly created role of Chief Medical Officer, based in the United States.

Todd Druley MD brings highly relevant clinical and business expertise to the planning, development, and commercialization of ANGLE’s diagnostics offerings through its clinical laboratories, regulatory filings, and pharma services.

Most recently, Dr. Druley held the position of Chief Medical Officer at ArcherDX, Inc., a genomic analysis company focused on precision oncology, where he established and grew its medical team before the Company was acquired by Invitae Corp. for up to US$1.4 billion in October 2020. During his tenure, he built an international team that successfully established new translational applications for ArcherDX assays and, in particular, its “Personalized Cancer Monitoring” assay, which is a patient-specific, bespoke assay for detecting 50 cancer-specific mutations from cell-free DNA in blood.

Dr. Druley brings a wealth of experience including 15 years at Washington University in St. Louis, Missouri, USA where he has published more than 60 peer-reviewed and invited manuscripts, many focusing on the methodology and application for identifying extremely rare mutations in complex human samples. His clinical focus was in leukaemia and he patented and licensed technology for error-corrected next-generation sequencing applicable for quantitative clonal haematopoiesis and molecular residual disease detection.

As Chief Medical Officer, Dr Druley will provide additional scientific, clinical and medical direction for ANGLE’s product development and will work with customers, collaborators and thought leaders in the liquid biopsy space to increase awareness and applications of the Parsortix® system. Dr Druley will also bring clinical and business perspectives to the planning, development, and commercialisation of ANGLE’s diagnostic offerings through its clinical laboratories, regulatory cleared products and pharma services.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

“We are delighted to welcome Todd to ANGLE and to the leadership team. We are looking forward to drawing on his deep expertise in both research and commercial settings as we develop our products and pharma services and work towards the launch of our first laboratory developed test and the future expansion of the clinical market for the Parsortix system.”

Dr. Todd Druley, Chief Medical Officer, ANGLE, added:

“I am extremely excited to join ANGLE as I believe the Company’s patented technology has the potential to improve outcomes for cancer patients worldwide. I look forward to progressing ANGLE’s strategy to demonstrate the high medical value of this leading liquid biopsy solution. I am confident that my clinical and industry experience will help to guide the clinical application and future regulatory approvals for the Parsortix system.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine